BIOVENTUS INC. - CLASS A COMMON STOCK

Bioventus Reports First Quarter Financial Results

07 May 2024 07:00:01 By Nasdaq GlobeNewswire

Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

29 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

12 Mar 2024 07:30:01 By Nasdaq GlobeNewswire

Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024

04 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

18 Jan 2024 16:15:00 By Nasdaq GlobeNewswire

Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole

12 Jan 2024 16:15:00 By Nasdaq GlobeNewswire

Bioventus Names Robert Claypoole as President and Chief Executive Officer

19 Dec 2023 16:30:00 By Nasdaq GlobeNewswire

Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

06 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance

07 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Bioventus to Present at the Cantor Global Healthcare Conference

19 Sep 2023 21:52:45 By Nasdaq GlobeNewswire

Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

06 Sep 2023 16:30:00 By Nasdaq GlobeNewswire

Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance

08 Aug 2023 07:30:01 By Nasdaq GlobeNewswire

Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference

04 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023

01 Aug 2023 17:35:30 By Nasdaq GlobeNewswire

Bioventus Completes Divestiture of its Wound Business

23 May 2023 07:30:00 By Nasdaq GlobeNewswire

Bioventus Reports First Quarter Financial Results

16 May 2023 16:15:00 By Nasdaq GlobeNewswire

Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023

15 May 2023 17:33:04 By Nasdaq GlobeNewswire

Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023

11 May 2023 07:00:02 By Nasdaq GlobeNewswire

Bioventus Announces Divestiture of its Wound Business

10 May 2023 09:00:00 By Nasdaq GlobeNewswire